Second-line treatment options in non-small cell lung cancer: A comparison of cytotoxic agents and targeted therapies

Seminars in Oncology

Volumn 33, Issue SUPPL. 1, 2006, Pages 17-24

  De Marinis, Filippo ^a   De Santis, Stefano ^a   De Petris, Luigi ^b  

^a Intensive Care Unit and Trauma Center   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CELECOXIB; CETUXIMAB; CYANOCOBALAMIN; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEFITINIB; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PEMETREXED; VANDETANIB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SCREENING; DRUG TARGETING; DYSPNEA; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; NEUTROPENIA; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; UNITED STATES; VITAMIN SUPPLEMENTATION;

EID: 32044461557     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.004     Document Type: Article

References (41)

1. D.G. Pfister, D.H. Johnson, C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline Update 2003 J Clin Oncol 22 2004 330 353
2. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
3. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
4. F.A. Shepherd, J. Dancey, R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
5. F.V. Fossella, R. DeVore, R.N. Kerr Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 2000 2354 2362
6. J. Dancey, F.A. Shepherd, R.J. Gralla Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy Results of a prospective, randomized phase III trial Lung Cancer 43 2004 183 194
7. 2) as second-line monotherapy for non-small-cell lung cancer Ann Oncol 15 2004 38 44
8. R. Gervais, A. Ducolone, J.L. Breton Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) Ann Oncol 16 2005 90 96
9. C. Camps, B. Massuti, A.M. Jimenez Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC) A Spanish Lung Cancer Group (SLCG) phase III trial Proc Am Soc Clin Oncol 22 2003 625 abstr 2514
10. W. Schuette, S. Nagel, M. Serke Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel Results of a randomized phase III study Proc Am Soc Clin Oncol 22 suppl 14S 2004 622s abstr 7036
11. C. Gridelli, C. Gallo, M. Di Maio A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer The DISTAL 01 study Br J Cancer 91 2004 1996 2004
12. D. Pectasides, M. Pectasides, D. Farmakis Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer A randomized phase II trial Ann Oncol 16 2005 294 299
13. V. Georgoulias, C. Kouroussis, A. Agelidou Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin A multicentre, randomised, phase II study Br J Cancer 91 2004 482 488
14. E.F. Smit, K. Mattson, J. von Pawel ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer A phase II study Ann Oncol 14 2003 455 460
15. C. Niyikiza, S.D. Baker, D.E. Seitz Homocysteine and methylmalonic acid Markers to predict and avoid toxicity from pemetrexed therapy Mol Cancer Ther 1 2002 545 552
16. S. Bhalla, N. Thatcher, M. Reck Does reporting expected duration and severity of adverse events provide clinically relevant information when selecting a chemotherapy regimen? An example using pemetrexed and docetaxel. Lung Cancer 49 suppl 2 2005 S85 S86 abstr PD-066
17. J.L. Pujol, S. Paul, U. Gatzemeier Risk-benefit of pemetrexed compared with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy An analysis of toxicity-free survival Ann Oncol 15 suppl 3 2004 iii186 abstr 705P
18. F. De Marinis, J.R. Pereira, K. Park Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxel. Proc Am Soc Clin Oncol 22 suppl 14S 2004 622s abstr 7035
19. E. Felip, R.A. Stahel, N. Pavlidis ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC Ann Oncol 16 suppl 1 2005 i28 i29
20. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial JAMA 290 2003 2149 2158
21. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
22. N. Thatcher, A. Chang, P. Parikh ISEL A phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens Lung Cancer 49 suppl 2 2005 S4 abstr Pr4
23. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
24. R. Rosell, M. Taron, J.M. Sanchez The promise of pharmacogenomics gemcitabine and pemetrexed Oncology (Williston Park 18 2004 70 76
25. C. Sarries, E.B. Haura, B. Roig Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer Pharmacogenomics 3 2002 763 780
26. F. Cappuzzo, E. Magrini, G.L. Ceresoli Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 2004 1133 1141
27. F. Cappuzzo, F.R. Hirsch, E. Rossi Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 2005 643 655
28. M. Taron, Y. Ichinose, R. Rosell Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas Clin Cancer Res 11 2005 5878 5885
29. X.L. Mu, L.Y. Li, X.T. Zhang Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer Clin Cancer Res 11 2005 4289 4294
30. D.H. Johnson, L. Fehrenbacher, W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
31. C. Aghajanian, S. Soignet, D.S. Dizon A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Clin Cancer Res 8 2002 2505 2511
32. R.S. Herbst, D.H. Johnson, E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
33. R. Perez-Soler, A. Chachoua, L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
34. F. De Marinis, L. Crino, G. Stynes Improved toxicity profile of pemetrexed vs docetaxel in previously treated non-small cell lung cancer patients translates to cost savings in Italy Ann Oncol 15 suppl 3 2004 iii190 abstr 719P
35. R. Lilenbaum, P. Bonomi, R. Ansari A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC Final results Proc Am Soc Clin Oncol 23 suppl 16S 2005 629s abstr 7036
36. E.S. Kim, A.M. Mauer, H.T. Tran A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer Final report Proc Am Soc Clin Oncol 22 2003 642 abstr 2581
37. T. Cufer, E. Vrdoljak Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer Proc Am Soc Clin Oncol 23 suppl 16S 2005 629s abstr 7035
38. J.V. Heymach, B.E. Johnson, J.A. Rowbottom A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC Proc Am Soc Clin Oncol 23 suppl 16S 2005 197s abstr 3023
39. R. Natale, D. Bodkin, R. Govindan A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa) in patients with NSCLC Results of a randomized, double-blind phase II study Lung Cancer 49 suppl 2 2005 S37 abstr O-103
40. M.P. Fanucchi, F. Fossella, P. Fidias Bortezomib ±docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC A phase 2 study Proc Am Soc Clin Oncol 23 2005 629s abstr 7034
41. R. Lilenbaum, M. Socinski, N. Altorki Phase II randomized trial of irinotecan/docetaxel or irinotecan/gemcitabine with or without celecoxib in 2nd-line treatment of non-small-cell lung cancer Lung Cancer 49 suppl 2 2005 S89 abstr PD-076